YS Biopharma Co., Ltd. (YS) | Investment Case

1. Company Snapshot

1.a. Company Description

YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer.It develops a proprietary PIKA immunomodulating technology platform and a series of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles.It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines.

The company was founded in 2002 and is based in Beijing, China.

Show Full description

1.b. Last Insights on YS

YS Biopharma Co., Ltd. experienced a -5.0% performance over the past three months, driven by the company's ongoing struggles to regain compliance with the Nasdaq's minimum bid price rule. The company's financial performance was also impacted by the repayment of its loan facility and the announcement of a name change to LakeShore Biopharma. Additionally, the company's pipeline of clinical trials, including the pivotal Phase 3 clinical study of PIKA Rabies Vaccine, may have contributed to the decline in stock price.

1.c. Company Highlights

Last Price	1.02
Change Percentage	9.68%
Open	0.9
Previous Close	0.93
Market Cap ( Millions)	192
Volume	102955
Year High	1.78
Year Low	0.35
M A 50	0.87
M A 200	0.66

FCF Yield	-56.73%
Dividend Yield	0.00%
ROE	-18.43%
Debt / Equity	82.92%
Net Debt / EBIDTA	-795.90%
Price To Book	1.27
Price Earnings Ratio	-6.35
Price To FCF	-1.76
Price To sales	0.4
EV / EBITDA	-13.0

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

YS Biopharma Announces Name Change to LakeShore Biopharma

May -24

Source: prnewswire.com

YS Biopharma Announces Results of Extraordinary General Meeting

May -21

Source: prnewswire.com

YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer

May -07

Source: prnewswire.com

YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

Apr -29

Source: prnewswire.com

YS Biopharma Co., Ltd. (YS) Q3 2024 Earnings Call Transcript

Apr -19

Source: Seeking Alpha

YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024

Apr -19

Source: prnewswire.com

YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine

Apr -18

Source: prnewswire.com

YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024

Apr -16

Source: prnewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.50%)

6. Segments

Biopharmaceutical Products

Expected Growth: 8.5%

Growing demand for biopharmaceuticals, increasing prevalence of chronic diseases, and advancements in biotechnology drive the market growth. YS Biopharma's diversified product portfolio and strong R&D capabilities position the company for success in this expanding market.

7. Detailed Products

PIKA COVID-19 Neutralizing Antibody Detection Kit

A rapid test kit for detecting neutralizing antibodies against SARS-CoV-2 in human serum or plasma

PIKA SARS-CoV-2 Antigen Detection Kit

A rapid test kit for detecting SARS-CoV-2 antigens in human nasopharyngeal swab or saliva samples

PIKA Influenza A/B Antigen Detection Kit

A rapid test kit for detecting influenza A and B antigens in human nasopharyngeal swab or throat swab samples

PIKA Respiratory Virus Detection Kit

A multiplex PCR kit for detecting multiple respiratory viruses, including influenza, RSV, and adenovirus

PIKA COVID-19 Vaccine Development Services

A comprehensive service for COVID-19 vaccine development, including antigen design, production, and testing

8. YS Biopharma Co., Ltd.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for YS Biopharma Co., Ltd. is moderate due to the presence of alternative products and services in the biopharmaceutical industry.

Bargaining Power Of Customers

The bargaining power of customers for YS Biopharma Co., Ltd. is low due to the company's strong brand reputation and limited availability of alternative products.

Bargaining Power Of Suppliers

The bargaining power of suppliers for YS Biopharma Co., Ltd. is moderate due to the presence of multiple suppliers in the market, but the company's large scale of operations gives it some bargaining power.

Threat Of New Entrants

The threat of new entrants for YS Biopharma Co., Ltd. is high due to the growing demand for biopharmaceutical products and the relatively low barriers to entry in the industry.

Intensity Of Rivalry

The intensity of rivalry for YS Biopharma Co., Ltd. is high due to the presence of several established players in the biopharmaceutical industry, leading to intense competition.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	40.64%
Debt Cost	6.14%
Equity Weight	59.36%
Equity Cost	6.61%
WACC	6.42%
Leverage	68.45%

11. Quality Control: YS Biopharma Co., Ltd. passed 2 out of 9 key points

Strong Liquidity

Low Deb

Strong Interest Coverage

Healthy Cash Flow

Operating Inefficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

MiMedx

A-Score: 5.0/10

Value: 3.1

Growth: 7.2

Quality: 8.5

Yield: 0.0

Momentum: 7.0

Volatility: 4.3

1-Year Total Return ->

UroGen Pharma

A-Score: 4.9/10

Value: 8.2

Growth: 5.6

Quality: 6.1

Yield: 0.0

Momentum: 9.0

Volatility: 0.7

1-Year Total Return ->

YS Biopharma

A-Score: 4.5/10

Value: 8.8

Growth: 4.6

Quality: 5.9

Yield: 0.0

Momentum: 6.0

Volatility: 2.0

1-Year Total Return ->

Armata Pharmaceuticals

A-Score: 4.4/10

Value: 8.0

Growth: 4.6

Quality: 6.1

Yield: 0.0

Momentum: 8.0

Volatility: 0.0

1-Year Total Return ->

Liquidia

A-Score: 4.0/10

Value: 6.0

Growth: 2.4

Quality: 3.2

Yield: 0.0

Momentum: 10.0

Volatility: 2.3

1-Year Total Return ->

Bionomics

A-Score: 3.6/10

Value: 3.9

Growth: 3.9

Quality: 8.2

Yield: 0.0

Momentum: 4.5

Volatility: 1.3

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

15.86%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

6.42%

YS Biopharma Co., Ltd. - KYG9845F1090

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on YS

1.c. Company Highlights

Weak Momentum

Higher Growth

Average Quality

Earnings Miss

Average Growth

Stable Momentum

Medium Volatility

Strong Momentum

Less Volatile

Lower Quality

Average Yield

Fairly Valued

Revenues Beats

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.50%)

6. Segments

Biopharmaceutical Products

Expected Growth: 8.5%

7. Detailed Products

PIKA COVID-19 Neutralizing Antibody Detection Kit

PIKA SARS-CoV-2 Antigen Detection Kit

PIKA Influenza A/B Antigen Detection Kit

PIKA Respiratory Virus Detection Kit

PIKA COVID-19 Vaccine Development Services

8. YS Biopharma Co., Ltd.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: YS Biopharma Co., Ltd. passed 2 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

1.02$

Current Price

1.02$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA